Navigation Links
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
Date:10/16/2007

- Data to be presented November 2 at the American Society of Nephrology

Meeting -

SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. Exelixis is continuing to analyze the data to assess whether further evaluation of the compound is warranted.

Proteinuria, the presence of excess protein in the urine, is an indicator of renal disease. Albumin excretion is a risk factor for kidney failure, stroke and cardiovascular and all-cause mortality, particularly in patients with diabetes and/or hypertension. Nephropathy (kidney disease) is a common problem in diabetic patients, often leading to the need for hemodialysis or kidney transplant. XL784 is a potent small molecule inhibitor of MMP2 and ADAM10, metalloprotease enzymes that may play a role in renal fibrosis and impairment.

"We obviously are disappointed that this trial did not meet its primary endpoint," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "However, the compound was well tolerated, and we are continuing to analyze the data to determine if the compound may have utility in the treatment of diabetic nephropathy. We will provide an update on our plans for XL784 once we complete our analysis of the data."

The complete safety and efficacy data from the phase 2 trial of XL784 in diabetic patients with proteinuria are scheduled for presentation on November 2, 2007, at the American Society of Nephrology (ASN) Renal Week 2007, which is b
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Aptuit LLC announces that Aptuit SSCI, ... , has enhanced its capabilities in the areas ... large molecules, including biologic drugs, metabolites, and polymers, ... mass spectrometer. In making the announcement, ... "The expanded large molecule capability enhances our early ...
(Date:8/21/2014)... Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... cancers and women,s health, has appointed Holly B. ... Markets. Ms. Bauzon has a proven track ... coverage for laboratory services companies. She has more than ... Inc., where she held the position of Director, Lab ...
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
Breaking Medicine Technology:Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... , FORT COLLINS, Colo., Dec. 14 Manchester Pharmaceuticals, ... (chenodiol tablets). On October 22, 2009, the US ... therapy for patients suffering from gallstones in whom surgery ... advanced age. , Chenodal prescriptions have started to be ...
... 14 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today ... the addition of Lt. Gen. Ronald R. Blanck, DO, U.S. ... Associates, a federal health services consulting firm based in Falls ... nine members. , Dr. Blanck began his military career in ...
Cached Medicine Technology:Manchester Announces Availability of Chenodal(TM) 2Oxygen Biotherapeutics, Inc. Expands Board of Directors 2
(Date:8/23/2014)... 23, 2014 A team of New York ... longer when preceded by surgery and delivered by an experienced ... new study. Click here to read it now . ... cases of mesothelioma patients who underwent hemithoracic (one ... dose to the shape of a tumor. Patients who ...
(Date:8/23/2014)... Board of Directors voted on Monday, August 18th to approve ... for commercial and industrial properties. This was accomplished with ... in Carmel, California. , This is a historical moment, ... the State of California has approved this technology for use ... can now be used as a sole source of water ...
(Date:8/23/2014)... TX (PRWEB) August 23, 2014 Youth ... of Texas. It’s no different in Houston, TX. Substance ... are falling victim to drug and alcohol dependency in ... are looking to beat substance abuse, but don’t know ... juvenile treatment facility can be a challenge because most ...
(Date:8/22/2014)... 23, 2014 The IT manager of ... hosting for several years. He has recently announced that ... hosting suppliers in 2014. , GoDaddy is a popular ... features and great hosting solutions at affordable rates. It ... for shared hosting plans depend on the length of ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 AWeber, ... services that currently helps more than 120,000 small ... caught the attention of Shane Michaels, prompting an investigative ... crucial element for any online marketing campaign, despite what ... in the marketing world,” reports Michaels. “AWeber is a ...
Breaking Medicine News(10 mins):Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2
... Mass., Nov. 25 Gene Network Sciences, Inc.,(GNS) ... company, Fina,Technologies, Inc. (Fina) to leverage its proprietary ... new arena -- that of,quantitative financial trading and ... raw clinical and genomics data to identify drug,targets, ...
... Season , , ROSELAND, N.J., ... during the busy holiday season. Unfortunately many get drawn into buying ... At airports, it,s easy to wind up eating unhealthy foods ... a rush or have time to spend before a flight, you ...
... Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that the ... Health Care Conference on December 3, 2008 at 2:30,p.m. Eastern ... Hotel in,New York City. Jack Lief, Arena,s President and Chief ... including its clinical,development and discovery programs. , ...
... /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian ... of drug products delivered to and through the skin, ... and development subsidiary, has signed a research and development ... develops and markets skin care products. Financial details of ...
... 25 Hillenbrand, Inc.,(NYSE: HI ) -- ... United States,District Court in the Southern District of Texas ... denied in,two previously disclosed antitrust lawsuits against Batesville Casket ... As previously reported, a purported consumer ...
... WELLINGTON, Fla., Nov. 25 The Quantum Group,Inc. ... solutions provider for,the healthcare industry, announced today that ... approval and a Certificate,of Authority from the State ... RASI has been established to provide administrative ...
Cached Medicine News:Health News:Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce 2Health News:Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce 3Health News:Nutritionist Claudia Gonzalez Shares Tips for Eating Well On-the-Go During the Busy Holiday Rush 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company 2Health News:Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company 3Health News:Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation 2Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 2Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 3Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 4
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... is the first ... to offer two kinds ... and taurine. Cleans, rinses, ... and conditions any soft ...
Medicine Products: